Emyria Delighted To Be Accepted Into Prestigious US Pain Ini...| MENAFN.COM

Tuesday, 31 January 2023 07:50 GMT

Emyria Delighted To Be Accepted Into Prestigious US Pain Initiative


(MENAFN- Media OutReach Limited) Melbourne, Victoria - News Direct - 30 November 2022 -






Emyria Ltd (ASX:EMD) Michael Winlo tells Proactive the company has been accepted into the US National Institute of Health's (NIH) Preclinical Screening Platform for Pain program. The NIH's National Institute of Neurological Disorders and Stroke (NINDS) — also the leading funder of neurological research in the US — will run the study as part of a broader initiative to stem the opioid public health crisis.
Hashtag: #Emyria
The issuer is solely responsible for the content of this announcement.

MENAFN29112022003551001712ID1105245145


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.